Cleveland-based ChanTest has tested more than 20,000 compounds for hundreds of pharmaceutical and biotech companies around the world since its founding in 1998. Over the years, the company has also developed a cell optimization service. These advancements have helped pharmaceutical and biotech companies develop safer drugs for a variety of health-related issues.

ChanTest has now formed an agreement with Molecular Devices, a Sunnyvale, California, company, to further its impact on the industry. Molecular Devices will distribute ChanTest's ion channels and promote its cell optimization services to a number of global customers.

Dr. Arthur Brown, founder of ChanTest, says that this partnership will benefit ChanTest because of the screening instrumentation provided by Molecular Devices. These include automated electrophysiology devices, which study the effects of electric activity in the body. "The ability to screen ion channels with automated electrophysiology is revolutionizing drug discovery," according to Dr. Brown.

ChanTest has a staff of 70 people, including scientists specializing in molecular and cell biology, chemistry and electrophysiology.

SOURCE: ChanTest
WRITER: Diane DiPiero